PBRM1 and nonpapillary renal cell carcinoma: Polybromo1 (PBRM1) is the second most frequently mutated in ccRCC, and PBRM1 mutation (MUT) has been shown to be strongly associated with improved survival with anti-PD-1 therapy [10–12].